WALTHAM, Mass.– Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of Gibco Efficient-Pro Medium (+) Insulin, a next-generation medium designed to deliver higher titers, faster workflows, and greater flexibility for insulin-dependent CHO cell lines.
The new medium, part of Thermo Fisher’s Efficient-Pro medium and feed system, is engineered to increase protein yield by as much as 61 percent compared with other alternatives, while streamlining workflow and handling for biopharma manufacturers, biotechnology companies, and contract development and manufacturing organizations (CDMOs). Efficient-Pro Medium (+) Insulin also maintains high viable cell densities and robust growth without compromising product quality, while supporting a broad range of insulin-dependent CHO cell lines in various formats and packaging configurations.
“Our announcement represents a significant enhancement in bioprocessing technology,” said Sara Henneman, vice president and general manager of Thermo Fisher Scientific’s cell culture and cell therapy business. “By integrating our AGT format and ensuring an AOF formulation, we are addressing key industry challenges and providing our customers with a reliable, high-performance solution. Efficient-Pro Medium (+) Insulin underscores our dedication to innovation and our mission to support the development of groundbreaking therapies that improve patient outcomes worldwide.”
The medium is formulated using Thermo Fisher’s Advanced Granulation Technology (AGT) dry media platform, which allows for ease of use, rapid reconstitution, and scalability. With its animal origin–free composition, Efficient-Pro Medium (+) Insulin reduces process variability and regulatory complexity, providing biopharma customers with more dependable results and greater confidence in production.
As the biologics industry increasingly demands faster development timelines, reduced costs, and supply chain resilience, Efficient-Pro Medium (+) Insulin offers a future-ready solution. By eliminating the need for manual insulin supplementation, the new medium simplifies bioproduction processes while maintaining rigorous quality systems for supply assurance.
“With Efficient-Pro Medium (+) Insulin, we’re building on our commitment to remove barriers in bioproduction and help our customers achieve more,” said Andy Campbell, senior director of research and development at Thermo Fisher Scientific. “This latest innovation enables our customers to scale up rapidly, adapt to evolving project needs, and accelerate the delivery of life-changing therapies to patients. Efficient-Pro Medium (+) Insulin delivers on that promise by providing the tools and support needed to streamline processes, minimize risk, and bring new treatments to market faster and more efficiently than ever before.”
